

ACTA MEDICINAE 2/2012 ONKOLOGIE

Kompletní literatura

- 2 **Informační zázemí onkologických screeningových programů ČR a jejich výsledky hodnocené z mezinárodního hlediska**
kolektiv autorů
- 2 **Chemoterapie a hormonální léčba karcinomu prsu**
MUDr. Katarína Petraková Klinika komplexní onkologické péče MOU, Brno
- 3 **Prevence nevolnosti a zvracení po chemoterapii**
doc. MUDr. Miroslav Tomáška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno
- 4 **Novinky v léčbě karcinomu prsu**
MUDr. Michal Vočka | MUDr. Zuzana Ušiaková | prof. MUDr. Luboš Petruželka, CSc.
Onkologická klinika 1. LF UK a VFN a ÚVN, Praha
- 5 **Projekt 35 – příliš mladá na karcinom prsu?**
doc. MUDr. Petra Tesařová, DrSc. Onkologická klinika 1. LF UK a VFN, Praha
- 5 **Nejnovější poznatky v léčbě pokročilého hepatocelulárního karcinomu**
prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK
a Thomayerovy nemocnice s poliklinikou, KOC (NNB, VFN a TN), Praha
- 5 **Biologická léčba nádorů ledvin**
doc. MUDr. Jindřich Fínek, Ph.D. Onkologické a radioterapeutické oddělení FN a LF UK, Plzeň
- 6 **Karcinom plic**
MUDr. Bohdan Kadlec | prof. MUDr. Jana Skříčková, CSc. | MUDr. Marcela Tomíšková
Klinika nemocí plicních a tuberkulózy LF MU a FN, Brno
- 7 **Komplexní léčba metastatického kolorektálního karcinomu**
MUDr. Igor Kiss, Ph.D. | MUDr. Jana Halámková
Klinika komplexní onkologické péče MOU a LF, Brno
- 7 **Karcinom žaludku**
MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOU, Brno
- 7 **Germinální nádory varlat – přehled diagnostiky a terapie**
MUDr. Tomáš Büchler, Ph.D. | prof. MUDr. Jitka Abrahámová, DrSc.
Onkologická klinika Fakultní Thomayerovy nemocnice s poliklinikou a 1. LF UK, Praha
- 8 **Současné možnosti léčby karcinomu slinivky břišní**
MUDr. Michal Vočka | prof. MUDr. Luboš Petruželka, CSc.
Onkologická klinika 1. LF UK a VFN a ÚVN, Praha
- 9 **Výživa onkologického pacienta**
doc. MUDr. Miroslav Tomáška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno
- 9 **Současné možnosti léčby průlomové bolesti onkologických pacientů**
MUDr. Ondřej Sláma, Ph.D. Ambulance podpůrné a paliativní onkologie,
Klinika komplexní onkologické péče MOU, Brno
- 10 **Léčba olanzapinem u pacientů se schizofrenií**
doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc
- 10 **Depresivní porucha a její léčba**
prof. MUDr. Ján Praško, CSc. | doc. MUDr. Klára Látalová, Ph.D.
Klinika psychiatrie FN Olomouc, LF UP, Olomouc
- 11 **Role mikroRNA při vzniku nádorů a možnosti jejich využití v léčbě**
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

Informační zázemí onkologických screeningových programů ČR a jejich výsledky hodnocené z mezinárodního hlediska

kolektiv autorů

- 1 Prorok, P. – Kramer, B. – Gohagan, J.: Screening Theory and Study Design: The Basics. In: Kramer, B. – Gohagan, J. – Prorok, P. (eds.): *Cancer Screening – Theory and Practice*. New York, Marcel Dekker, 1999.
- 2 Rada Evropské unie: *Doporučení rady ze dne 2. prosince 2003 o screeningu zhoubných nádorů*. On-line ec.europa.eu/health/ph_information/dissemination/diseases/docs/cancer_recommendation_cs.pdf, cit. 20. 8. 2008.
- 3 Arbyn, M. – Anttila, A. – Jordan, J. – Ronco, G. – Schenck, U. – Segnan N., et al.: *European guidelines for quality assurance in cervical cancer screening, 2nd ed.* Luxembourg, European Communities, 2008.
- 4 Perry, N. – Broeders, M. – de Wolf, C. – Tornberg, S. – Holland, R. – von Karsa, L., et al. (eds.): *European guidelines for quality assurance in breast cancer screening and diagnosis, 4th ed.* Luxembourg, Office for Official Publications of the EC, 2006.
- 5 Segnan, N. – Patnick, J. – von Karsa, L. (eds.): *European guidelines for quality assurance in colorectal cancer screening and diagnosis*. Luxembourg, Publications Office of the European Union, 2010.
- 6 Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. – Vyzula, R.: *Epidemiologie zhoubných nádorů v České republice*. On-line <http://www.svod.cz>. 2007, cit. 2009.
- 7 Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. – Vyzula, R.: *Epidemiologie zhoubných nádorů v České republice*. 2005, www.svod.cz, cit. 14. 9. 2009.
- 8 Pavlík, T. – Dušek, L. – Májek, O. – Žaloudík, J.: Five-Year Survival Rates of Cancer Patients in the Czech Republic. In: Dušek, L., et al. (eds.): *Czech Cancer Care in Numbers 2008–2009*. Praha, Grada Publishing, 2009.
- 9 Pavlík, T. – Májek, O. – Muzik, J. – Koptikova, J. – Slavicek, L. – Finek, J., et al.: Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. *BMC Public Health*, 2012, 12 (1), s. 117.
- 10 Nystrom, L. – Andersson, I. – Bjurstam, N. – Frisell, J. – Nordenskjold, B. – Rutqvist, L. E.: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. *Lancet*, 2002, 359 (9310), s. 909–919.
- 11 Mandel, J. S. – Bond, J. H. – Church, T. R. – Snover, D. C. – Bradley, G. M. – Schuman, L. M., et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. *N Engl J Med*, 1993, 328 (19), s. 1365–1371.
- 12 Hakama, M. – Rasanen-Virtanen, U.: Effect of a mass screening program on the risk of cervical cancer. *Am J Epidemiol.* 1976, 103 (5), s. 512–517.
- 13 Day, N. – Williams, D. – Khaw, K.: Breast cancer screening programmes: the development of a monitoring and evaluation system. *Br J Cancer*, 1989, s. 954–958.
- 14 Lieberman, D. – Nadel, M. – Smith, R. A. – Atkin, W. – Duggirala, S. B. – Fletcher, R., et al.: Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. *Gastrointest Endosc*, 2007, 65 (6), s. 757–766.
- 15 Vainio, H. – Bianchini, F. (eds.): *Breast Cancer Screening*. Lyon, IARC Press, 2002.
- 16 Althuis, M. D. – Dozier, J. M. – Anderson, W. F. – Devesa, S. S. – Brinton, L. A.: Global trends in breast cancer incidence and mortality 1973–1997. *Int J Epidemiol*, 2005, 34 (2), s. 405–412.
- 17 Brenner, H. – Gondos, A. – Arndt, V.: Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. *J Clin Oncol*, 2007, 25 (22), s. 3274–3280.
- 18 de Vries, E. – Karim-Kos, H. E. – Janssen-Heijnen, M. L. – Soerjomataram, I. – Kiemeneij, L. A. – Coebergh, J. W.: Explanations for worsening cancer survival. *Nat Rev Clin Oncol*, 2010, 7 (1), s. 60–63.
- 19 Karsa, L. – Anttila, A. – Ronco, G. – Ponti, A. – Malila, N. – Arbyn, M., et al.: *Cancer Screening in the European Union: Report on the implementation of the Council Recommendation on cancer screening*. Luxembourg, European Communities, 2008.
- 20 Zavoral, M. – Suchanek, S. – Zavada, F. – Dusek, L. – Muzik, J. – Seifert, B., et al.: Colorectal cancer screening in Europe. *World J Gastroenterol*, 2009, 15 (47), s. 5907–5915.
- 21 Májek, O. – Danes, J. – Skovajsova, M. – Bartonkova, H. – Buresova, L. – Klimes, D., et al.: Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme. *BMC Public Health*, 2011, 11, s. 288.
- 22 Mansmann, U. – Crispin, A. – Henschel, V. – Adrion, C. – Augustin, V. – Birkner, B., et al.: Epidemiology and quality control of 245 000 outpatient colonoscopies. *Dtsch Arztebl Int*, 2008, 105 (24), s. 434–440.
- 23 Kaminski, M. F. – Regula, J. – Kraszewska, E. – Polkowski, M. – Wojciechowska, U. – Didkowska, J., et al.: Quality indicators for colonoscopy and the risk of interval cancer. *N Engl J Med*, 2010, 362 (19), s. 1795–1803.

Chemoterapie a hormonální léčba karcinomu prsu

MUDr. Katarína Petráková Klinika komplexní onkologické péče MOU, Brno

- 1 Kaufmann, M. – von Minckwitz, G. – Bear, H. D., et al.: Recommendation from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. *Ann Oncol*, 2007, 18 (12), s. 1927–1934.
- 2 Ring, A. E. – Smith, I. E. – Ashley, S., et al.: Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. *Br J Cancer*, 2004, 91, s. 2012–2017.
- 3 Goldhirsch, A. – Wood, W. C. – Gelber, R. D., et al.: Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann Oncol*, 2011, 22 (8), s. 1736–1747.
- 4 Fischer, B. – Neony, J. H. – Bryant, J., et al.: Treatment of lymph-node-negative, oestrogen receptor positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. *Lancet*, 2004, 364, s. 858–868.
- 5 Albain, K. – Barlow, W. – O'Malley, F., et al.: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamid, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesteron (PgR) receptor-positive breast cancer: mature outcomes and new biological correlates on phase III intergroup trial 0100 (SWOG-8814). *Breast Cancer Res Treat*, 2004, 88 (dopl. 1), abs. 37.
- 6 Henderson, I. C. – Berry, D. A. – Demetri, G. D., et al.: Improved

- outcomes from adding sequential paclitaxel, but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. *J Clin Oncol*, 2003, 21, s. 976–983.
- 7 Roche, H. – Fumoleau, P. – Spielman, M., et al.: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. *J Clin Oncol*, 2006, 24 (36), s. 5664–5671.
 - 8 Francis, P. – Crown, J. – Di Leo, A., et al.: BIG 02-98 Collaborative Group. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. *J Natl Cancer Inst*, 2008, 100 (2), s. 121–133.
 - 9 Martin, M. – Pienkowski, T. – Mackey, J., et al.: Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. *N Engl J Med*, 2005, 352 (22), s. 2302–2313.
 - 10 Jones, et al.: *Breast Cancer Res Treat*, 2007, 106 (dopl. 1), s. S5, abs. 12.
 - 11 Cuzik, J. – Ambrosine, L. – Davidson, N., et al.: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a metaanalysis of individual patient data from randomised adjuvant trials. *Lancet*, 2007, 369, s. 1711–1723.
 - 12 Peto, R. – Davies, C., and the ATLAS investigators: ATLAS (Adjuvant Tamoxifen Longer Against Shorter): international randomised trial of 10 vs 5 years of adjuvant tamoxifen among 11,500 women: preliminary results. *Breast Cancer Res Treat*, 2007, 106 (dopl. 1), s. S00, abs. 48.
 - 13 Rea, D. W. – Hanley, K. – Marshall, M., et al.: aTTom (adjuvant Tamoxifen-To offer more?): Randomised trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor positive (ER+) or ER untested breast cancer- Preliminary results. *Proc Am Soc Clin Oncol*, 2008, abs. 513.
 - 14 Forbes, J. F. – Cuzick, J. – Buzdar, A., et al.: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. *Lancet Oncol*, 2008, 9, s. 45–53.
 - 15 Coates, A. S. – Kashaviah, A. – Thurlimann, B., et al.: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. *J Clin Oncol*, 2007, 25, s. 486–492.
 - 16 Goss, P. E. – Unyle, J. N. – Martino, S., et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: update findings from NIC CTG MA17. *J Natl Cancer Inst*, 2005, 97, s. 1262–1271.
 - 17 Carrick, S. – Parker, S. – Wilcken, N., et al.: Single agent versus combination chemotherapy for metastatic breast cancer. *Cochrane Database Syst Rev*, 2005, 2, Art No. CD003372, doi: 10.1002/14651858.
 - 18 Bruzzi, P. – Del Mastro, L. – Formani, M. P., et al.: Objective response to chemotherapy as a potential surrogate and point of survival in metastatic breast cancer patients. *J Clin Oncol*, 2005, 23, s. 5117–5125.
 - 19 Greenberg, P. A. – Hortobagyi, G. N. – Smith, T. L., et al.: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. *J Clin Oncol*, 1996, 14, s. 2197–2205.
 - 20 Nabholz, J. M. – Falkon, C. – Campos, D., et al.: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. *J Clin Oncol*, 2003, 21, s. 968–975.
 - 21 Jassem, J. – Pienkowski, T. – Pluzanska, A., et al.: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III multicenter trial. *J Clin Oncol*, 2001, 19, s. 1707–1715.
 - 22 Boneneterre, J. – Thurlimann, B. – Robertson, J. F., et al.: Anastrozole versus tamoxifen in first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. *J Clin Oncol*, 2000, 18, s. 3748–3757.
 - 23 Nabholz, J. M. – Buzdar, A. – Pollak, M., et al.: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. *J Clin Oncol*, 2000, 18, s. 3758–3767.
 - 24 Howell, A. – Robertson, J. F. – Abram, P., et al.: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomised trial. *J Clin Oncol*, 2004, 22, s. 1605–1613.
 - 25 Klijn, J. G. – Blamey, R. W. – Boccardo, F., et al.: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomised trials. *J Clin Oncol*, 2001, 19, s. 343–353.

Prevenční nevolnosti a zvracení po chemoterapii

doc. MUDr. Miroslav Tomáška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno

- 1 Grunberg, S. – Deuson, R. R. – Mavros, P., et al.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. *Cancer*, 2004, 100, s. 2261–2268.
- 2 Roila, F. – Herrstedt, J. – Aapro, M., et al.: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. *Ann Oncol*, 2010, 21 (dopl. 5), s. v232–v243.
- 3 Ettinger, D. S., and Pannel Members: *NCCN Clinical Practice Guidelines in Oncology*. Version 1.2012. //www.nccn.org/professionals/physician_gls/.
- 4 Ellebaek, E. – Herrstedt, J.: Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. *Current Opinion in Supportive and Palliative Care*, 2008, 2, s. 28–34.
- 5 Schwartzberg, L. – Szabo, S. – Gilmore, J., et al.: Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately and highly emetogenic chemotherapy (LEC, MEC, HEC). *Curr Med Res Opin*, 2011, 27, s. 837–845.
- 6 Hesketh, P. J. – Aapro, M. – Street, J. C. – Carides, A. D.: Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. *Support Care Cancer*, 2010, 18 (9), s. 1171–1177.
- 7 Warr, D. G. – Street, J. C. – Carides, A. D.: Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. *Support Care Cancer*, 2011, 19 (6), s. 807–813.
- 8 Rojas, C. – Thomas, A. G. – Alt, J., et al.: Palonosetron triggers 5-HT₃ receptor internalization and causes prolonged inhibition of receptor function. *European J Pharmacol*, 2010, 626, s. 193–199.
- 9 Navari, R. M.: Prevention of emesis from multiple-day and high-dose chemotherapy regimens. *J Natl Compr Cancer Network*, 2007, 5, s. 51–59.
- 10 Warr, D. G. – Grunberg, S. M. – Gralla, R. J. – Hesketh, P. J. – Roila, F. – de Wit, R., et al.: The oral NK₁ antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled

trials. *Eur J Cancer*, 2005, 41, s. 1278–1285.

- 11 Botrel, T. E. – Clark, O. A. – Clark, L., et al.: Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT₃R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. *Support Care in Cancer*, 2011, 19, s. 823–832.
- 12 Rapoport, B. L. – Jordan, K. – Boice, J. A., et al.: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with broad spectrum of moderately emetogenic chemotherapies and tumor types: a randomized, double blind study. *Support Care Cancer*, 2009, doi: 10.1007/s00520-009-0680-9.
- 13 Grunberg, S. – Clark-Snow, R. A. – Koeller, J.: Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. *Support Care Cancer*, 2010, 18 (dopl. 1), s. S1–S10.
- 14 Bash, E. – Prestrud, A. A. – Hesketh, P. J. – Kris, M. G., et al.: Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*, 2011, doi: 10.1200/JCO.2010.34.4614.

Novinky v léčbě karcinomu prsu

MUDr. Michal Vočka | MUDr. Zuzana Ušiaková | prof. MUDr. Luboš Petruželka, CSc.

Onkologická klinika 1. LF UK a VFN a ÚVN, Praha

- 1 Petruželka, L.: Současné možnosti a nové perspektivy systémové léčby karcinomu prsu. *Klin Farmakol Farm*, 21, 2007, s. 11–17.
- 2 Petruželka, L.: Karcinom prsu – jak dál v diagnostice a léčbě ve světle nových možností. *Vnitř Léč*, 53, 2007, s. 22–23.
- 3 Petruželka, L.: Nové možnosti léčby ErbB2 a hormonálně dependentních karcinomů prsu. *Klin. Farmakoter*, 2012, v tisku.
- 4 Higgins, M. J. – José Baselga, J.: Targeted therapies for breast cancer. *J Clin Invest*, 2011, 121 (10), s. 3797–3803.
- 5 Tang, R. Y. – Finn, R. S.: Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. *British Journal of Cancer*, 2012, 106, s. 6–13.
- 6 Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*, 344, 2001, s. 783–790.
- 7 Pegram, M. D. – Konecny, G. E. – O’Callaghan, C., et al.: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. *J Natl Cancer Inst*, 2004, 96, s. 739–745.
- 8 Petruželka, L.: Biologická léčba karcinomu prsu. *Onkologie*, 3, 2009, s. 19–27.
- 9 Baselga, J. – Cortés, J. – Kim, S.-B., et al.: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*, 2011, 366 (2), s. 109–119.
- 10 Lewis Phillips, G. D. – Li, G. – Dugger, D. L., et al.: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. *Cancer Res*, 2008, 68, s. 9280–9290.
- 11 Beeram, M. – Burris, H. A. – Modi, S. – Birkner, M. – Girish, S. – Tibbitts, J.: A phase I study of trastuzumab-DM1 (T-DM1), a first in class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). *Proc Am Soc Clin Oncol*, 2008, 26, abstr. 1028.
- 12 Krop, I. E. – Mita, M. – Burris, H. A., et al.: A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer. Prezentováno: 31st Annual San Antonio Breast Cancer Symposium; 10.–14. 12. 2008; San Antonio, TX. Abstrakt 3136.
- 13 Vogel, C. L. – Burris, H. A. – Limentani, S., et al.: A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. *Proc Am Soc Clin Oncol*, 2009, 27 (dopl. 15), abstr. 1017.
- 14 Alvarez, R. H. – Valero, V. – Gabriel, N. – Hortobagyi, G. N.: Emerging Targeted Therapies for Breast Cancer. *J Clin Oncol*, 2010, 28, s. 3366–3379.
- 15 Jordan, M. A. – Kamath, K. – Manna, T., et al.: The primary antimetabolic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. *Mol Cancer Ther*, 2005, 4, s. 1086–1095.
- 16 Okouneva, T. – Azarenko, O. – Wilson, L., et al.: Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. *Mol Cancer Ther*, 2008, 7, s. 2003–2011.
- 17 Towle, M. J. – Salvato, K. A. – Budrow, J., et al.: In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. *Cancer Res*, 2001, 61, s. 1013–1021.
- 18 Goel, S. – Mita, A. C. – Mita, M., et al.: A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid tumors. *Clin Cancer Res*, 2009, 15, s. 4207–4212.
- 19 Tan, A. R. – Rubin, E. H. – Walton, D. C., et al.: Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors. *Clin Cancer Res*, 2009, 15, s. 4213–4218.
- 20 Vahdat, L. T. – Pruitt, B. – Fabian, C. J., et al.: Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol*, 2009, 27, s. 2954–2961.
- 21 Cortes, J. – Vahdat, L. – Blum, J. L., et al.: Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. *J Clin Oncol*, 2010, 28, s. 3922–3928.
- 22 Iwata, H. – Aogi, K. – Masuda, N., et al.: Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. *J Clin Oncol*, 2010, 28, s. 1081.
- 23 Twelves, C. – Loesch, D. – Blum, J. L., et al.: A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol*, 2010, 28, abstr. CRA1004.
- 24 Cigler, T. – Vyndat, L.: Eribulin mesylate for the treatment of breast cancer. *Expert Opin. Pharmacother*, 2010, 11 (9), s. 1587–1593.
- 25 Cortes, J. – O’Shaughnessy, J. – Losech, D., et al.: Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet*, 2011, 377, s. 914–923.
- 26 Hortobagyi, G. N.: Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. 2011 San Antonio Breast Cancer Symposium. Updated late breaking abstract No. S3-7, 7. 12. 2011.
- 27 Dawood, S. – Broglio, K. – Giordano, S. H., et al.: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. *J Clin Oncol*, 2010, 28 (1), s. 92–98.

Projekt 35 – příliš mladá na karcinom prsu?

doc. MUDr. Petra Tesařová, DrSc. Onkologická klinika 1. LF UK a VFN, Praha

- 1 **Parkin, D. M.:** Cancers attributable to exposure to hormones in the UK in 2010. *Br J Cancer*, 2011, 105 (S2), s. S42–S48.
- 2 **Sidoni, A. – Cavaliere, A. – Bellezza, G. – Scheibel, M. – Bucciarelli, E.:** Breast cancer in young women: clinicopathological features and biological specificity. *Breast*, 2003, 12 (4), s. 247–250.
- 3 **Ménard, S. – Casalini, P. – Cascinelli, N. – Balsari, A.:** Breast carcinoma in young patients. *Lancet*, 2000, 356 (9235), s. 1113, 1123.
- 4 **Jmor, S. – Al-Sayer, H. – Heys, S. D. – Payne, S. – Miller, I. – Ah-See, A. – Hutcheon, A. – Eremin, O.:** Breast cancer in women aged 35 and under: prognosis and survival. *J R Coll Surg Edinb*, 2002, 47 (5), s. 693–699.
- 5 **Hartmann, S. – Reimer, T. – Gerber, B.:** Management of early invasive breast cancer in very young women (<35 years). *Clin Breast Cancer*, 2011, 11 (4), s. 196–203.
- 6 **Francis, P. A.:** Optimal adjuvant therapy for very young breast cancer patients. *Breast*, 2011, 20 (4), s. 297–302.
- 7 **de Bree, E. – Makrigiannakis, A. – Askoxylikis, J. – Melissas, J. – Tsiftsis, D. D.:** Pregnancy after breast cancer. A comprehensive review. *J Surg Oncol*, 2010, 101 (6), s. 534–542.
- 8 **Hulvat, M. C. – Jeruss, J. S.:** Maintaining fertility in young women with breast cancer. *Curr Treat Options Oncol*, 2009, 10 (5–6), s. 308–317.

Nejnovější poznatky v léčbě pokročilého hepatocelulárního karcinomu

prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK a Thomayerovy nemocnice s poliklinikou, KOC (NNB, VFN a TN), Praha

- 1 **Chen, C. J. – Liang, K. Y. – Chang A. S., et al.:** Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. *Hepatology*, 1991, 13, s. 398–406.
- 2 **Fattovich, G. – Ribero, M. L. – Pantalena, M., et al.:** Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. *J Viral Hepat*, 2001, 8, s. 206–216.
- 3 **Wilhelm, S. – Carter, C. – Lynch, M., et al.:** Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. *Nat Rev Drug Discov*, 2006, 5, s. 835–844.
- 4 **Llovet, J. M. – Bruix, J.:** Novel advancements in the management of hepatocellular carcinoma in 2008. *J Hepatol*, 2008, 48 (dopl. 1): s. S20–S37.
- 5 **Llovet, J. M. – Bruix, J.:** Molecular targeted therapies in hepatocellular carcinoma. *Hepatology*, 2008, 48, s. 1312–1327.
- 6 **Cheng, A. L. – Kang, Y. K. – Chen, Z., et al.:** Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo controlled trial. *Lancet Oncol*, 2009, 10, s. 25–34.
- 7 **Česká onkologická společnost ČLS JEP.:** Zásady cytostatické léčby onkologických onemocnění 2011. Dostupné z <http://www.linkos.cz/informace-pro-praxi/zasady-cytostaticke-lecby/> [cit. 4. 5. 2012].
- 8 **Yoon, S. K. – Ye, S. L. – Marrero, J., et al.:** GIDEON (Global Investigation of therapeutic DEcision in Hepatocellular Carcinoma and Of its treatment with sorafenib) interim results: regional subgroup analysis. *Hepatol Int*, 2011, 5, 3–558, FC02–05.
- 9 **Abrahámová, J.:** Postavení sorafenibu v současné medikamentózní léčbě hepatocelulárního karcinomu. In: *Farmakoterapie – Léčba hepatocelulárního karcinomu 2011*, 2011, 7 (speciální příloha), s. 32–39.
- 10 **Kupec, M. – Büchler, T. – Abrahámová, J.:** Dlouhodobé přežití pacienta s pokročilým hepatocelulárním karcinomem léčeného sorafenibem. In: *Farmakoterapie – Léčba hepatocelulárního karcinomu 2011*, 2011, 7 (speciální příloha), s. 40–41.
- 11 **American Society of Clinical Oncology 2012 Gastrointestinal Cancers Symposium**, 19.–21. leden 2012, San Francisco, Kalifornie.

Biologická léčba nádorů ledvin

doc. MUDr. Jindřich Fínek, Ph.D. Onkologické a radioterapeutické oddělení FN a LF UK, Plzeň

- 1 **Escudier, B. – Pluzanska, A. – Koralewski, P., et al.:** Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. AVOREN Trial investigators. *Lancet*, 2007, 370 (9605), s. 2103–2111.
- 2 **Rini, B. I. – Halabi, S. – Rosenberg, J. E., et al.:** Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. *J Clin Oncol*, 2010, 28 (13), s. 2137–2143.
- 3 **Motzer, R. J. – Michaelson, M. D. – Redman, B. G., et al.:** Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2006, 24 (1), s. 16–24.
- 4 **Motzer, R. J. – Rini, B. I. – Bukowski, R. M., et al.:** Sunitinib in patients with metastatic renal cell carcinoma. *JAMA*, 2006, 295 (21), s. 2516–2524.
- 5 **Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.:** Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med*, 2007, 356 (2), s. 115–124.
- 6 **Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.:** Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2009, 27 (22), s. 3584–3590.
- 7 **Hudes, G. – Carducci, M. – Tomczak, P., et al.:** Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Global ARCC Trial. *N Engl J Med*, 2007, 356 (22), s. 2271–2281.
- 8 **Sternberg, C. N. – Davis, I. D. – Mardiak, J., et al.:** Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *J Clin Oncol*, 2010, 28 (6), s. 1061–1068, e-pub 25. 1. 2010.

- 9 Escudier, B. – Eisen, T. – Stadler, W. M., et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. TARGET Study Group. *N Engl J Med*, 2007, s. 356 (2), s. 125–134.
- 10 Escudier, B. – Szczylík, C. – Hutson, T. E.: Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2009, 27 (8), s. 1280–1289, e-pub 26. 1. 2009. Erratum in: *J Clin Oncol*, 2009, 27 (13), s. 2305.
- 11 Stadler, W. M. – Figlin, R. A. – McDermott, D. F., et al.: ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. *Cancer*, 2010, 116 (5), s. 1272–1280.
- 12 Beck, J. – Bajetta, E. – Escudier, B., et al.: A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor Sorafenib in European patients with advanced renal cell carcinoma. *European Journal of Cancer Suppl*, 2007, 5, 300 s. 4506.
- 13 Motzer, R. J. – Escudier, B. – Oudard, S., et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. RECORD-1 Study Group. *Lancet*, 2008, 372 (9637), s. 449–456.
- 14 SPC Votrient, červen 2010.
- 15 CHMP assessment report/Votrient, 14. 6. 2010, www.ema.europa.eu.
- 16 Sternberg, C. N. – Davis, I. D. – Mardiak, J., et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. *J Clin Oncol*, 2010, 28, s. 1061–1068.
- 17 Sternberg, C. N. – Szczylík, C. – Lee, E., et al.: A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Presentation at the 45th Annual Meeting American Society of Clinical Oncology, Orlando, Florida, 29. 5.–2. 6. 2009.
- 18 Hutson, T. E., et al.: Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2010, 28 (3), s. 475–480.

Karcinom plic

MUDr. Bohdan Kadlec | prof. MUDr. Jana Skříčková, CSc. | MUDr. Marcela Tomíšková

Klinika nemocí plicních a tuberkulózy LF MU a FN, Brno

- 1 Adam, Z., et al.: Systémové a paraneoplastické projevy maligních onemocnění. *Vnitř Léč*, 2007, 53 (3), s. 253–285.
- 2 Demedts, I. K. – Vermaelen, K. Y. – van Meerbeeck, J. P.: Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. *Eur Respir J*, 2010, 35, s. 202–215.
- 3 Gao, G. – Ren, S. – Li, A. – Xu, J. – Xu, Q. – Su, C. – Guo, J. – Deng, Q. – Zhou, C.: Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. *Int J Cancer*, 2011, doi: 10.1002/ijc.27396.
- 4 Goldstraw, P. – Crowley, J. – Chansky, K. – Giroux, D. J. – Groome, P. A., et al.: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. *J Thorac Oncol*, 2007, 2, s. 706–714.
- 5 Goldstraw, P. – Crowley, J. J.: The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer. *J Thorac Oncol*, 2006, 1, s. 281–286.
- 6 Hansen, M.: Paraneoplastic syndromes and tumor markers for small-cell and non-small-cell lung cancer. *Curr Opin Oncol*, 1990, 2, s. 345–351.
- 7 Johnson, B. E. – Janne, P. A.: Basic treatment considerations using chemotherapy for patients with small cell lung cancer. *Hematol Oncol Clin North Am*, 2004, 18, s. 309–322.
- 8 Molina, J. R. – Dusi, A. A. – Jett, J. R.: Advances in Chemotherapy of Non-small Cell Lung Cancer. *CHEST*, 2006, 130, s. 1211–1219.
- 9 Murray, N. – Turrisi, A. T.: A review of first-line treatment for small-cell lung cancer. *J Thorac Oncol*, 2006, 1, s. 270–278.
- 10 NSCLC Meta-Analyses Collaborative Group: Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials. *J Clin Oncol*, 2008, 26, s. 4617–4625.
- 11 Patel, S. – Macdonald, O. K. – Suntharalingam, M.: Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. *Cancer*, 2009, 115, s. 842–850.
- 12 Pešek, M., et al.: *Bronchogenní karcinom*. Praha, Galén, 2002.
- 13 Pešek, M. – Skříčková, J. – Kolek, V. – Zatloukal, P. – Petruželka, L. – Tomíšková, M. – Krákorová, G. – Grygárková, I. – Havel, P. – Zemanová, M. – Minárik, M. – Svobodník, A. – Dušek, L. – Chroust, K. – Kaiserová, P. – Šlégrová, Z. – Berkovcová, J. – Hajdúch, M.: Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České republice. *Studia Pneumologica et Phthiseologica*, 2009, 69, 2, s. 61–68.
- 14 Pijls-Johannesma, M. – De Ruyscher, D. – Vansteenkiste, J., et al.: Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. *Cancer Treat Rev*, 2007, 33, s. 461–473.
- 15 Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol*, 2009, 27 (14), s. 2415.
- 16 Rosell, R. – Carcereny, E. – Gervais, R. – Vergnenegre, A. – Massuti, B. – Felip, E., et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*, 2012, 13, s. 239–246.
- 17 Scott, W. J. – Howington, J. – Feigenberg, S., et al.: Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest*, 2007, 132, s. 2345.
- 18 Sculier, J. – Pand Moro-Sibilot, D.: First-and second-line therapy for advanced nonsmall cell lung cancer. *Eur Respir J*, 2009, 33, s. 915–930.
- 19 Secretan, B. – Straif, K. – Baan, R., et al.: A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. *Lancet Oncol*, 2009, 10, s. 1033–1034.
- 20 Shepherd, F. A. – Crowley, J. – van Houtte, P. – Postmus, P. E. – Carney, D., et al.: The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. *J Thorac Oncol*, 2007, 2, s. 1067–1077.
- 21 Shepherd, F. A. – Evans, W. K. – Feld, R., et al.: Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. *J Clin Oncol*, 1988, 6, s. 832–838.
- 22 Schneider, B. J.: Management of recurrent small cell lung cancer. *J Natl Compr Canc Netw*, 2008, 6, s. 323–331.
- 23 Simon, M. – Argiris, A. – Murren, J. R.: Progress in the therapy of small cell lung cancer. *Crit Rev Oncol Hematol*, 2004, 49, s. 119–133.
- 24 Skříčková, J., et al.: Bronchogenní karcinom (41–62). In: Adam, Z. – Vorlíček, J. – Vaníček, J., et al.: *Diagnostické a léčebné postupy u maligních*

chorob. Grada Publishing, Praha, 2004.

- 25 Yu, J. B. – Decker, R. H. – Detterbeck, F. C. – Wilson, L. D.: Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. *J Thorac Oncol*, 2010, 5, s. 215–219.
- 26 Zatloukal, P. – Petruželka, L.: *Karcinom plic*. Praha, Grada, 2001.

- 27 Zhou, C. – Wu, Y. L. – Chen, G. – Feng, J. – Liu, X. Q. – Wang, C., et al.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*, 2011, 12, s. 735–742.

Komplexní léčba metastatického kolorektálního karcinomu

MUDr. Igor Kiss, Ph.D. | MUDr. Jana Halámková

Klinika komplexní onkologické péče MOU a LF, Brno

- 1 Software pro vizualizaci onkologických dat (SVOD), www.svod.cz.
- 2 Screening kolorektálního karcinomu, www.kolorektum.cz.
- 3 Van Cutsem, E. – Kohne, C. H. – Hitre, E., et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med*, 2009, 360, s. 1408–1417.
- 4 Hurwitz, H. – Fehrenbacher, L. – Novotny, W., et al.: *N Engl J Med*, 2004, 350, s. 2335–2342.
- 5 Saltz, L. B. – Clarke, S. – Díaz-Rubio, E., et al.: Bevacizumab in combination with oxaliplatin based chemotherapy as first line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol*, 2008, 26, s. 2013–2019.
- 6 Bismuth, H. – Adam, R. – Levi, F., et al.: Resection of nonresectable liver metastase from colorectal cancer after neoadjuvant chemotherapy. *Ann Surg*, 1996, 224, s. 509–522.
- 7 Adam, R. – Wicherts, D. A. – de Haas, R. J., et al.: Patient wit initially unresectable colorectal liver metastase : is there a possibility of cure? *J Clin Oncol*, 2009, 27, s. 1829–1835.
- 8 Nordlinger, B. – Skrbte, H. – Glimelius, B., et al.: Preoperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. *Lancet*, 2008, 371, s. 1007–1016.
- 9 Kubala, E. – Bartoš, J. – Petruželka, L., et al.: Safety and effectiveness of bevacizumab in combination with chemotherapy in patients with metastatic colorectal cancer in elderly population: updated results from a large Czech observational registry. *ASCO GI*, 2010.

Karcinom žaludku

MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOU, Brno

- 1 Cunningham, D. – Allum, W. H. – Stenning, S. P., et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med*, 2006, 355, s. 11–20.
- 2 Macdonald, J. S. – Smalley, S. R. – Benedetti, J., et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med*, 2001, 345, s. 725–730.
- 3 Wagner, A. D. – Grothe, W. – Haerting, J., et al.: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. *J Clin Oncol*, 2006, 24, s. 2903–2909.
- 4 Cunningham, D. – Starling, N. – Rao, S., et al.: Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med*, 2008, 358 (1), s. 36–46.
- 5 Van Cutsem, E. – Moiseyenko, V. M. – Tjulandin, S., et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a Report of the V325 Study Group. *J Clin Oncol*, 2006, 24, s. 4991–4997.
- 6 Ajani, J. A. – Moiseyenko, V. M. – Tjulandin, S., et al.: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a Phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. *J Clin Oncol*, 2007, 25, s. 3210–3216.
- 7 Moehler, M. – Eimermacher, A. – Siebler, J., et al.: Randomized Phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. *Br J Cancer*, 2005, 92, s. 2122–2128.
- 8 Van Cutsem, E. – Kang, Y. – Chung, H., et al.: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in firstline human epidermal growth factor receptor 2-positive advanced gastric cancer. *J Clin Oncol*, 2009, 27 (15S), LBA4509.

Germinální nádory varlat – přehled diagnostiky a terapie

MUDr. Tomáš Büchler, Ph.D. | prof. MUDr. Jitka Abrahámová, DrSc.

Onkologická klinika Fakultní Thomayerovy nemocnice s poliklinikou a 1. LF UK, Praha

- 1 Dušek, L. – Mužík, J. – Kubásek, M., et al.: *Epidemiologie zhoubných nádorů v České republice*. Masarykova univerzita, 2005, cit. 4. 10. 2012, <http://www.svod.cz>.
- 2 McGlynn, K. A. – Cook, M. B.: Etiologic factors in testicular germ-cell tumors. *Future Oncol*, 2009, 5 (9), s. 1389–1402.
- 3 International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. *J Clin Oncol*, 1997, 15, s. 594–603.
- 4 Capelouto, C. C. – Clark, P. E. – Ransil, B. J., et al.: A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? *J Urol*, 1995, 153, s. 981–985.
- 5 Abrahámová J.: Léčebné postupy u nepokročilých testikulárních germinálních nádorů neseminomového typu. *Klinická onkologie*, 2008, 21,

- 3, s. 81–85.
- 6 **Abrahámová J.**: Radioterapie germinálních nádorů. In: Abrahámová, J. – Dušek, L. – Povýšil, C., et al.: *Nádory varlat*, Grada, 2008, s. 195–205.
 - 7 **Krege, S. – Beyer, J. – Souchon, R. – et al.**: European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. *Eur Urol*, 2008, 53 (3), s. 497–513.
 - 8 **Kondagunta, G. V. – Bacik, J. – Donadio, A., et al.**: Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. *J Clin Oncol*, 2005, 23 (27), s. 6549–6555.
 - 9 **Einhorn, L. H. – Williams, S. D. – Chamness, A., et al.**: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. *N Engl J Med*, 2007, 357 (4), s. 340–348.
 - 10 **Fossa, S. D. – Bokemeyer, C. – Gerl, A., et al.**: Treatment outcome of patients with brain metastases from malignant germ cell tumors. *Cancer*, 1999, 85, s. 988–997.
 - 11 **Buchler, T. – Kubankova, P. – Boublikova, L., et al.**: Detection of second malignancies during long-term follow-up of testicular cancer survivors. *Cancer*, 2011, 117, s. 4212–4218.

Současné možnosti léčby karcinomu slinivky břišní

MUDr. Michal Vočka | prof. MUDr. Luboš Petruželka, CSc.

Onkologická klinika 1. LF UK a VFN a ÚVN, Praha

- 1 **Hidalgo, M.**: Pancreatic Cancer. *N Engl J Med*, 2010, 362, s. 1605–1617.
- 2 **Verdecchia, A. – Francisci, S. – Kunkler, I., et al.**: Recent cancer survival in Europe: a 2000–02 period analysis of EURO CARE-4 data. *Lancet Oncology*, 2007, 8 (9), s. 784–796.
- 3 **Roazzi, P. – Capocaccia, R. – Santaquilani, M. – Carrani, E.**: Electronic availability of EURO CARE-3 data: a tool for further analysis. *Ann Oncol*, 2003, 14 (dopl. 5), s. 150–155.
- 4 www.svod.cz.
- 5 **Dušek, L., et al.**: *Czech Cancer Care in Numbers 2008–2009*. Grada Publishing, Praha, 2009.
- 6 **Hanash, S. M., et al.**: Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. *Nat. Rev. Clin. Oncol*, 2011, 8, s. 142–150.
- 7 **Abramson, M. A. – Zajac, A. – van der Zee, J. A. – Whang, E. E.**: The Molecular Biology of Pancreatic Cancer. *Gastrointest Cancer Res*, 2007, 1, s. 7–12.
- 8 **Cascinu, S. – Falconi, M. – Valentini, V. – Jelic, S.**: On behalf of the ESMO Guidelines Working Group: Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 2010, 21, s. 55–58.
- 9 **Chang, D. K. – Johns, A. L., et al.**: Margin Clearance and Outcome in Resected Pancreatic Cancer. *J Clin Oncol*, 2010, 27, s. 2855–2862.
- 10 **Balcom, J. H. – Rattner, D. W. – Warshaw, A. L. – Chang, Y. – Fernandez-del, C. C.**: Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. *Arch Surg*, 2001, 136, s. 391–398.
- 11 **Birkmeyer, J. D. – Finlayson, S. R. – Tosteson, A. N. – Sharp, S. M. – Warshaw, A. L. – Fisher, E. S.**: Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. *Surgery*, 1999, 125, s. 250–256.
- 12 **Stocken, D. D. – Buchler, M. W. – Dervenis, C. – Bassi, C. – Jeekel, H. – Klinkenbijn, J. H., et al.**: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. *Br J Cancer*, 2005, 92, s. 1372–1381.
- 13 **GITSG**. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. *Cancer*, 1987, 59, s. 2006–2010.
- 14 **Klinkenbijn, J. H. – Jeekel, J. – Sahnoud, T. – van Pel, R. – Couvreur, M. L. – Veenhof, C. H., et al.**: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. *Ann Surg*, 1999, 230, s. 776–782.
- 15 **Neoptolemos, J. P. – Dunn, J. A. – Stocken, D. D. – Almond, J. – Link, K. – Beger, H., et al.**: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. *Lancet*, 2001, 358, s. 1576–1585.
- 16 **Regine, W. F. – Winter, K. W. – Abrams, R. – Safran, H. – Hoffman, J. P. – Kanski, A., et al.**: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. *J Clin Oncol*, 2006, 24, No. 18S: 4007.
- 17 **Ben-Josef, E. – Lawrence, T. S.**: The importance of local kontrol in pancreatic cancer. *Clin Oncol*, 2012, 9, s. 9–10.
- 18 **Stathis, A. – Moore, M. J.**: Advanced pancreatic carcinoma: current treatment and future challenges. *Nat. Rev. Clin. Oncol*, 7, 2010, s. 163–172.
- 19 **Huguet, F. – Girard, N. – Guerche, C. S. – Hennequin, C. – Mornex, F. – Azria, D.**: Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. *J Clin Oncol*, 2009, 27, s. 2269–2277.
- 20 **Heinemann, V. – Boeck, S. – Hinke, A. – Labianca, R. – Louvet, C.**: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. *BMC Cancer*, 2008, 8, s. 82–85.
- 21 **Conroy, T., et al.**: FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. *N Engl J Med*, 2011, 364, s. 1817–1825.
- 22 **Tempero, M. A., et al.**: Pancreatic cancer treatment and research: an international expert panel discussion. *Ann Oncol*, 2011, s. 93–99.
- 23 **Philip, P., et al.**: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. *J Clin Oncol*, 2007, 25, s. a4509.
- 24 **Van Cutsem, E. – Vervenne, W. – Bennouna, J., et al.**: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *J Clin Oncol*, 2008, 27, s. 2231–2237.
- 25 **Kindler, H. L. – Priberg, G. – Singh, D. A., et al.**: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. *J Clin Oncol*, 2005, 23, s. 8033–8040.
- 26 **Van Cutsem, E. – van de Velde, H. – Karasek, P., et al.**: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. *J Clin Oncol*, 2004, 22, s. 1430–1438.
- 27 **Moore, M. J., et al.**: Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol*, 2007, 25, s. 1960–1966.
- 28 **Pelzer, U. – Stieler, J., et al.**: A randomised second line trial in patients with gemcitabine refractory advanced pancreatic cancer- CONKO 003. *J Clin Onco*, 2007, 25 (dopl.), s. 201.
- 29 **Harsha, H. C. – Kandasamy, K. – Ranganathan, P., et al.**: A compendium of potential biomarkers of pancreatic cancer. *PLoS Med*, 2009, 6 (4), s. e1000046.
- 30 **Burris, H. A., et al.**: *J Clin Oncol*, 1997, 15, s. 2403–2413.
- 31 **Conroy, T., et al.**: ASCO, 2010, abstrakt 4010.

Výživa onkologického pacienta

doc. MUDr. Miroslav Tomáška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno

- 1 **Andreyev, H. J. N. – Norman, A. R. – Oates, J. – Cunningham, D.:** Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? *Eur J Cancer*, 1998, 34, s. 503–509.
- 2 **Awad, S. – Tan, B. J. – Cui, H., et al.:** Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. *Clin Nutrition*, 2012, 31, s. 74–77.
- 3 **Barber, M. D. – Ross, J. A. – Fearon, K. C. H.:** Cancer cachexia. *Surg Oncol*, 1999, 8, s. 133–141.
- 4 **Braga, M. – Gianotti, L. – Radaelli, G., et al.:** Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized double-blind phase 3 trial. *Arch Surg*, 1999, 134 (4), s. 428–433.
- 5 **Camps, C. – Iranzo, V. – Bremnes, R. M. – Sira, R.:** Anorexia-cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. *Supp Care Cancer*, 2006, 14, s. 1173–1183.
- 6 **Davidson, W. – Ash, S. – Capra, S., et al.:** Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. *Clin Nutrition*, 2004, 23, s. 239–247.
- 7 **Fearon, K. C. H. – Barber, M. D. – Moses, A. G., et al.:** Double-blind, placebo controlled, randomised study of eicosapentaenoic acid diester in patients with cancer cachexia. *J Clin Oncol*, 2006, 24, s. 3401–3407.
- 8 **Hoda, D. – Jatoi, A. – Burnes, J., et al.:** Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution's 20-years experience. *Cancer*, 2005, 103, s. 863–868.
- 9 **Khalid, U. – Spiro, A. – Baldwin, C., et al.:** Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. *Supp Care Cancer*, 2007, 15, s. 39–46.
- 10 **McMillan, D. C. – Watson, W. S. – Preston, T. – McArdle, C. S.:** Lean body mass changes in cancer patients with weight loss. *Clinical Nutrition*, 2000, 19, s. 403–406.
- 11 **Moses, A. W. G. – Slater, C. – Preston, T., et al.:** Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. *Br J Cancer*, 2004, 90, s. 996–1002.
- 12 **Nitenberg, G. – Raynard, B.:** Nutritional support of the cancer patient: issues and dilemmas. *Critical Review in Oncology/Hematology*, 2000, 34, s. 137–168.
- 13 **Ovesen, L. – Allingstrup, L. – Hannibal, J. – Mortensen, E. L. – Hansen, O. P.:** Effect of dietary counselling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: A prospective, randomized study. *J Clin Oncol*, 1993, 11, s. 2043–2049.
- 14 **Ravasco, P. – Monteiro-Grillo, I. – Vidal, P. M., et al.:** Dietary counselling improves patient outcomes: a prospective, randomized controlled trial in colorectal cancer patients undergoing radiotherapy. *J Clin Oncology*, 2005, 23, s. 1431–1438.
- 15 **Tisdale, M. J.:** Cachexia in cancer patients. *Nature Reviews*, 2002, 2, s. 862–871.
- 16 **Zadák, Z.:** Enterální výživa u pacientů s nádorovým onemocněním. In: Wilhelm, Z., et al.: *Výživa v onkologii*. Institut pro další vzdělávání pracovníků ve zdravotnictví, Brno, 2001.

Současné možnosti léčby průlomové bolesti onkologických pacientů

MUDr. Ondřej Sláma, Ph.D. Ambulance podpůrné a paliativní onkologie,
Klinika komplexní onkologické péče MOU, Brno

- 1 **Davies, A. M. – Dickman, A. – Reid, C., et al.:** The management of cancer-related breakthrough pain: Recommendations of a taskgroup of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. *European Journal of Pain*, 2009, 13, s. 331–338.
- 2 **Haugen, D. F. – Hjermstad, M. J. – Hagen, N., et al.:** Assessment and classification of cancer breakthrough pain: A systematic literature review. *Pain*, 2010, 149, s. 476–482.
- 3 **Kabelka, L. – Lejčko, J. – Kozák, J. – Sláma, O.:** Doporučený postup pro léčbu průlomové nádorové bolesti. *Farmakoterapie*, 2011, 7 (5), s. 521–523.
- 4 **Portenoy, R. K. – Forbes, K. – Lussier, D. – Hanks, G.:** Difficult pain problems: an integrated approach. In: Doyle, D. – Hanks, G. – Cherny, N. – Calman, K. (eds.): *Oxford textbook of palliative medicine*. Oxford, Oxford University Press, 2004, s. 438–458.
- 5 **Sláma, O. – Lejčko, J. – Kozák, J., et al.:** Epidemiologie a léčba průlomové bolesti u onkologických pacientů v ČR. Výsledky výzkumného projektu PARMA. Část 1. Prevalence a klinické charakteristiky průlomové bolesti. *Bolest*, 2011, 14 (1), s. 158–160.
- 6 **Mercadante, S. – Villari, P. – Ferrera, P. – Casuccio, A.:** Optimization of opioid therapy for preventing incident pain associated with bone metastases. *J Pain Sympt Manage*, 2004, 28, s. 505–510.

Léčba olanzapinem u pacientů se schizofrenií

doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc

- 1 Breier, A. – Meehan, K. – Birkett, M., et al.: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. *Arch Gen Psychiatry*, 2002, 59, s. 441–448.
- 2 Hill, A. L. – Sun, B. – Karagianis, J. L., et al.: Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. *BMC Psychiatry*, 2011, 15, s. 11–28.
- 3 Kane, J. M. – Detke, H. C. – Naber, D., et al.: Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. *Am J Psychiatry*, 2010, 167, s. 181–189.
- 4 Komossa, K. – Rummel-Kluge, C. – Hunger, H., et al.: Olanzapine versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*, 2010, 3, CD006654.
- 5 Lauriello, J. – Lambert, T. – Andersen, S., et al.: An 8-week, double blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. *J Clin Psychiatry*, 2008, 69, s. 790–799.
- 6 Leucht, S. – Komossa, K. – Rummel-Kluge, C., et al.: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. *Am J Psychiatry*, 2009, 166, s. 152–163.
- 7 Lieberman, J. A. – Stroup, T. S. – McEvoy, J. P., et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*, 2005, 353, s. 1209–1223.
- 8 Meehan, K. – Zhang, F. – David, S. – Tohen, M., et al.: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. *J Clin Psychopharmacol*, 2001, 21, s. 389–397.
- 9 Meehan, K. M. – Wang, H. – David, S. R. – Nisivoccia, J. R., et al.: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. *Neuropsychopharmacology*, 2002, 26, s. 494–504.
- 10 Wright, P. – Birkett, M. – David, S. R., et al.: Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. *Am J Psychiatry*, 2001, 158, s. 1149–1151.

Depresivní porucha a její léčba

prof. MUDr. Ján Praško, CSc. | doc. MUDr. Klára Látalová, Ph.D.

Klinika psychiatrie FN Olomouc, LF UP, Olomouc

- 1 American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). *Am J Psychiatry*, 2000, 157 (dopl.), s. 1–45.
- 2 Bauer, M. – Bschor, T. – Kuntz, D. – Berhöfer, A. – Stöhle, A. – Müller-Oerlinghausen, B.: Double blind, placebo controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. *Am J Psychiatry*, 2000, 157, s. 1429–1435.
- 3 Beck, A. T. – Rush, A. J. – Shaw, B. F. – Emery, G.: *Cognitive Therapy of Depression*. New York, Guilford, 1979.
- 4 Clinical Guidelines for The Treatment of Depressive Disorders (Clinical Practice Guidelines). *The Canadian Journal of Psychiatry*, 2001, 46 (dopl. 1), s. 91.
- 5 Crismon, M. L. – Trivedi, M. – Pigott, T. A. – Rush, A. J. – Hirschfeld, R. M. – Kahn, D. A. – De Battista, C. – Nelson, J. C. – Nierenberg, A. A. – Sackeim, H. A. – Thase, M. E.: The Texas Algorithm Project: report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder. *J Clin Psychiatry*, 1999, 60, s. 142–156.
- 6 El-khalili, N. – Joyce, M. – Atkinson, S.: *Adjunctive extended-release quetiapine fumarate in patients with major depressive disorder and inadequate antidepressant response*. 16th Annual Meeting of the American Psychiatric Association, Washington DC, USA, 2008.
- 7 Frank, E. – Prien, R. F. – Jarrett, R. B. – Keller, M. B. – Kupfer, D. J. – Lavori, P. W. – Rush, A. J. – Weissmann, M. M.: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. *Arch Gen Psychiatry*, 1991, 48, s. 851–855.
- 8 Geddes, J. R. – McCarney, S. M. – Davies, C. – Furukawa, T. A. – Kupper, D. J. – Goodwin, G. M.: Relapse prevention with antidepressant drug treatment in depressive disorder: a systematic review. *Lancet*, 2003, 361, s. 653–661.
- 9 Kessler, R. C. – Berglund, P. – Demler, O., et al.: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA*, 2003, 289, s. 3095–3105.
- 10 McPherson, S. – Cairns, P. – Carlyle, J. – Shapiro, D. A. – Richardson, P. – Taylor, D.: The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. *Acta Psychiatr Scand*, 2005, 111 (5), s. 331–340.
- 11 *Mezinárodní klasifikace nemocí*. 10. revize. Duševní poruchy a poruchy chování: Popisy klinických příznaků a diagnostická vodítka (přeloženo z anglického originálu). Praha, Psychiatrické centrum, 1992, Zprávy č. 102.
- 12 Montgomery, S. – Cutler, A. – Lazarus, E.: Extended release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. 16th European Congress of Psychiatry, Nice, Francie, 2008.
- 13 Moore, R. G. – Garland, A.: *Cognitive Therapy for Chronic and Persistent Depression*. Chichester, John Wiley and Sons, 2003.
- 14 Murray, C. J. – Lopez, A. D.: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. *Lancet*, 1997, 349, s. 1498–1504.
- 15 Praško, J.: Bright light therapy. *Neuroendocrinology Letters*, 2008, 29 (dopl. 1), s. 33–64.
- 16 Quitkin, F. M. – McGrath, J. P. – Stewart, J. W.: Chronological milestones to guide drug change: when should clinician switch antidepressant? *Arch Gen Psychiatry*, 1996, 53, s. 785–792.
- 17 Rush, A. J. – Trivedi, M. H. – Wisniewski, S. R. – Nierenberg, A. A. – Stewart, J. W. – Warden, D., et al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry*, 2006, 163 (11), s. 1905–1917.
- 18 Segal, Z. – Williams, J. M. – Teasdale, J.: *Mindfulness-based cognitive therapy for depression*. New York, The Guilford Press, 2002.
- 19 Thase, M. E. – Friedman, E. S. – Howland, R. H.: Management of treatment-resistant depression: psychotherapeutic perspectives. *J Clin Psychiatry*, 2001, 62 (dopl. 18), s. 18–24.

- 20 **Thase, M. E.:** Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. *J Clin Psychiatry*, 1998, 59, s. 502–508.
- 21 **Thase, M. E.:** Relapse and recurrence in unipolar major depression: Short-term and long-term approaches. *J Clin Psychiatry*, 1990, 5 (dopl.), s. 51–57.
- 22 **Weisler, R. – Joyce, M. – Mc Gill, L.:** *Extended release quetiapine fumarate monotherapy for major depressive disorder (MDD): a double-blind placebo-controlled study.* American Psychiatric Association, Washington D. C., USA, 2008.
- 23 **Weissman, M. M. – Leaf, P. J. – Tischler, G. L., et al.:** Affective disorders in five United States communities. *Psychol Med*, 1988, 18, s. 141–153.
- 24 **WHO:** *WHO Report 2001: Mental Health. New Hope: New Understanding.* 2001, kapitola 2: Burden of Mental and Behavioral Disorders.
- 25 World Health Organization, Mental Health Collaborating Centers, 1989.

Role mikroRNA při vzniku nádorů a možnosti jejich využití v léčbě

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 **Lujambio, A. – Lowe, S. W.:** The microcosmos of cancer. *Nature*, 2012, 484, s. 347–355.
- 2 **Calin, G. A. – Dumitru, C. D. – Shimizu, M. – Bichi, R. – Zupo, S. – Noch, E. – Adler, H. – Rattan, S. – Keating, M. – Rai, K. – Rassenti, L. – Kipps, T. – Negrini, M. – Bullrich, F. – Croce, C. M.:** Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proceedings of the National Academy of Sciences*, 2002, 99, s. 15524–15529.
- 3 **Lu, J. – Getz, G. – Miska, E. A. – Alvarez-Saavedra, E. – Lamb, J. – Peck, D. – Sweet-Cordero, A. – Ebert, R. L. – Mak, R. H. – Ferrando, A. A. – Downing, J. R. – Jacks, T. – Horvitz, H. R. – Golub, T. R.:** MicroRNA expression profiles classify human cancers. *Nature*, 2005, 435, s. 834–838.
- 4 **Yanaihara, N. – Caplen, N. – Bowman, E. – Seike, M. – Kumamoto, K. – Yi, M. – Stephens, R. M. – Okamoto, A. – Yokota, J. – Tanaka, T. – Calin, G. A. – Liu, C.-G. – Croce, C. M. – Harris, C. C.:** Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer Cell*, 2006, 9, s. 189–198.
- 5 **Mitchell, P. S. – Parkin, R. K. – Kroh, E. M. – Fritz, B. R. – Wyman, S. K. – Pogosova-Agadjanyan, E. L. – Peterson, A. – Noteboom, J. – O'Briant, K. C. – Allen, A. – Lin, D. W. – Urban, N. – Drescher, C. W. – Knudsen, B. S. – Stirewalt, D. L. – Gentleman, R. – Vessella, R. L. – Nelson, P. S. – Martin, D. B. – Tewari, M.:** Circulating microRNAs as stable blood-based markers for cancer detection. *Proceedings of the National Academy of Sciences*, 2008, 105, s. 10513–10518.
- 6 **Thomson, J. M. – Newman, M. – Parker, J. S. – Morin-Kensicki, E. M. – Wright, T. – Hammond, S. M.:** Extensive post-transcriptional regulation of microRNAs and its implications for cancer. *Genes & Development*, 2006, 20, s. 2202–2207.
- 7 **Chang, T.-C. – Yu, D. – Lee, Y.-S. – Wentzel, E. A. – Arking, D. E. – West, K. M. – Dang, C. V. – Thomas-Tikhonenko, A. – Mendell, J. T.:** Widespread microRNA repression by Myc contributes to tumorigenesis. *Nature Genetics*, 2008, 40, s. 43–50.
- 8 **Johnson, S. M. – Grosshans, H. – Shingara, J. – Byrom, M. – Labourier, E. – Reinert, K. L. – Brown, D. – Slack, F. J.:** RAS is regulated by the let-7 MicroRNA Family. *Cell*, 2005, 120, s. 635–647.
- 9 **He, L. – He, X. – Lowe, S. W. – Hannon, G. J.:** microRNAs join the p53 network – another piece in the tumor-suppression puzzle. *Nature Reviews Cancer*, 2007, 7, s. 819–822.
- 10 **Su, X. – Chakravarti, D. – Cho, M. S. – Liu, L. – Gi, Y. J. – Lin, Y.-L. – Leung, M. L. – El-Naggar, A. – Creighton, C. J. – Suraoka, M. B. – Wistuba, I. – Flores, E. R.:** TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. *Nature*, 2010, 467, s. 986–990.
- 11 **Godlewski, J. – Nowicki, M. O. – Bronisz, A. – Nuovo, G. – Palatini, J. – De Lay, M. – Van Brocklyn, J. – Ostrowski, M. C. – Chiocca, E. A. – Lawler, S. E.:** MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. *Molecular Cell*, 2010, 37, s. 620–632.
- 12 **Anand, S. – Majeti, B. K. – Murphy, L. M. – Mukthavaram, R. – Schepke, L. – Huang, M. – Shields, D. J. – Lindquist, J. N. – Lapinski, P. E. – King, P. D. – Weis, S. M. – Chersesh, D. A.:** MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. *Nature Medicine*, 2010, 16, s. 909–914.